Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2019 Feb 20;18(4):801–811. doi: 10.1158/1535-7163.MCT-18-1167

Figure 5: Tumor growth of ARRB2-OE and ARRB2-sh transfectants.

Figure 5:

A, B: Xenograft tumors were generated by injecting 1 × 106 HT1376-EV or HT1376 ARRB2-OE cells subcutaneously into nude mice. Xenograft tumor growth, and response to Gemcitabine treatment was monitored weekly. Gem (25 mg/kg bodyweight) was administered intraperitoneally, twice per week. C, D, E: Analysis of CD44s, CD44v, ARRB2, and cytokeratin mRNA levels in HT1376 subcutaneous tumor xenografts by qPCR. Norm. levels: target mRNA levels normalized to β-Actin mRNA.